Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BC004
- Development stage
- Phase 1
- Lead developer
- Sichuan Luzhou Buchang Biopharmaceutical
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BC004 is a recombinant humanized bispecific antibody that targets both HER2 (ERBB2) and CD3. It is designed to treat HER2-positive advanced solid tumors by simultaneously binding to the HER2 receptor on tumor cells and the CD3 receptor on T cells, thereby redirecting T cell cytotoxicity toward cancer cells. The drug is administered intravenously and is currently in early clinical development. Its primary indications include HER2-positive breast cancer, gastric cancer, gastroesophageal junction adenocarcinoma, and other advanced solid tumors with HER2 overexpression or low expression[1][2][3][5]. There are no approved drugs with this exact target combination currently available.
- Other names
- BC004 for injectionBC-004 for injectionBC 004 for injectionrecombinant anti-HER2/CD3 humanized bispecific antibody
02
Targets
CD3 (T-cell surface glycoprotein CD3)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on BC004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BC004.